Aviragen Therapeutics (AVIR) Tops Q1 EPS by 2c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Stardust Power (SDST) Tops Q2 EPS by 1c